Adherium Ltd. ( (AU:ADR) ) has shared an update.
Adherium Limited has secured $2.6 million through a convertible note capital raise, with significant contributions from Bioscience Managers and Trudell Medical International. The funds will support the expansion of Adherium’s Hailie® Smartinhaler® platform in the United States, aiming to onboard 1,800 active patients in the next six months and 9,000 by the end of 2025. This financial backing is seen as a positive indicator of the company’s growth prospects and its strategic focus on the US market, where it plans to capitalize on new reimbursement codes and advanced AI capabilities.
More about Adherium Ltd.
Adherium Limited is a leading digital health company specializing in respiratory health management. The company focuses on the development and commercialization of the Hailie® Smartinhaler® platform, which is designed to improve medication adherence for patients with respiratory conditions such as COPD and asthma. Adherium aims to leverage AI and clinical validation to become a global leader in proactive respiratory illness management.
Average Trading Volume: 964,577
Technical Sentiment Consensus Rating: Buy
Current Market Cap: A$7.59M
For detailed information about ADR stock, go to TipRanks’ Stock Analysis page.